30 closest matches · ranked by relevance
Chronic Myelomonocytic Leukemia · de Novo Myelodysplastic Syndromes · Myelodysplastic Syndromes
Primary: Number of Patients With Response as Defined by IWG (International Working Group) Criteria for Myelodysplasia — 7; 4; 0; 9 participants
Leukemia, Myeloid, Acute · Myelodysplastic Syndromes
Primary: Phase I: Maximum Tolerated Dose (MTD) of LBH589 When Given in Combination With Decitabine — 40 mg (level 5b dosing schedule)
Chronic Myelomonocytic Leukemia · de Novo Myelodysplastic Syndrome · Myelodysplastic Syndrome
Primary: Failure-free Survival (Failure Defined as Death or Relapse) — 6; 10 Participants
Myelodysplastic Syndrome
Primary: Overall Response Rate (ORR): Number of Participants Who Achieved Either Complete Remission (CR), Partial Remission (PR), or Marrow Complete Remission (mCR)…
Myelodysplastic Syndrome
Primary: One Year Overall Survival of Allogeneic Transplant Recipients After Transplantation — 50 percentage of participants
Myelodysplastic Syndrome
Primary: Event Free Survival (EFS) at 1 Year — 26; 65 percentage of participants
Acute Myelogenous Leukemia · Myelodysplastic Syndrome
Primary: Number of Participants With a Response (Complete Remissions (CR), Complete Remissions With Incomplete Platelet Recovery [CRp] and Partial Responses) — 1; 1; 0 participants
Leukemia · Myelodysplastic Syndromes
Primary: PHASE I: Maximum Tolerated Dose of Azacitidine — 75 mg/m2 subcutaneously for 5 days
Myelodysplastic Syndrome
Primary: The Number of Patients Who Achieved a Clinical Response — 5 Participants
Myelodysplastic Syndromes · Thrombocytopenia
Primary: Number of Participants With Response Between Weeks 16 and 20 — 11 Participants
de Novo Myelodysplastic Syndromes · Previously Treated Myelodysplastic Syndromes · Secondary Myelodysplastic Syndromes
Primary: Number of Confirmed Responses (Complete Response, Partial Response, or Hematologic Improvement) Noted on 2 Consecutive Evaluations at Least 4 Weeks Apart — 1; 0; 0…
Myelodysplastic Syndromes
Primary: Number of Participants With Confirmed Responses (Complete Remission, Partial Remission, or Hematologic Improvement) as Defined by the International Working Group…
de Novo Myelodysplastic Syndromes · Previously Treated Myelodysplastic Syndromes · Secondary Myelodysplastic Syndromes
Primary: Frequency of Hematologic Responses, as Defined by International Working Group (IWG) Criteria — 14; 8; 1; 7 Participants
Myelodysplastic Syndromes · Myeloproliferative Neoplasm
Primary: Overall Survial Time — 18.3 months
High Risk Myelodysplastic Syndrome
Primary: Number of Participants With a Complete Response (CR) — 25 Participants
Leukemia · Myelodysplastic Syndromes · Myelodysplastic/Myeloproliferative Neoplasms
Primary: Number of Participants With Response — 0; 0; 3; 1 participants
Chronic Myelomonocytic Leukemia · de Novo Myelodysplastic Syndromes · Myelodysplastic Syndromes
Primary: Overall Response Rate (Complete Response, Partial Response, or Hematologic Improvement) Defined by the International Working Group Criteria — 10 percentage of participants
Myelodysplastic Syndromes
Primary: Number of Participants Who Experienced an Adverse Event — 6 participants
Myelodysplastic Syndromes · Secondary Acute Myeloid Leukemia
Primary: Maximum Tolerated Dose of CD8 Depleted Non-engrafting HLA-mismatched Unrelated Donor Lymphocytes Infusion (NE-DLI) — 5 10^7 CD4 cells/kg
MDS
Primary: Percentage of Participants With at Least One Red Blood Cell (RBC) Transfusion During the Double-blind Treatment Period — 59.2; 36.1 percentage of participants — p=0.008
Myelodysplastic Syndromes
Primary: Number of Participants Evaluated for Hematologic and Nonhematologic Toxicities as Measured by NCI CTC v2.0 — 5; 14; 7; 28 Participants
Leukemia · Leukemia, Myeloid · Monocytic Leukemia
Primary: Clinical Response: Hematological Improvement - Erythroid (HI-E) — 0; 0 participants
Myelodysplastic Syndrome
Primary: Response Signature in Transfusion Dependent MDS Patients — 24; 1; 17; 6 Participants
Acute Myeloid Leukemia · Blasts 30 Percent or Less of Bone Marrow Nucleated Cells · Chronic Myelomonocytic Leukemia
Primary: Proportion or Participants Experiencing a Dose-limiting Toxicity — 0.0 percentage of participants
Myelodysplastic Syndrome
Primary: The Overall Improvement Rate — 23.3; 22.7; 16.3; 0 Percentage of Participants
Myelodysplastic Syndrome
Primary: Percentage of Participants With Response — 23.5 Percentage of Participants
Mixed Phenotype Acute Leukemia · Previously Treated Myelodysplastic Syndrome · Recurrent Adult Acute Myeloid Leukemia
Primary: Number of Participants Experiencing Dose Limiting Toxicities (DLTs) at the Maximum Tolerated Dose (MTD) for Decitabine When Given Together With G-CLAM Toxicities (DLTs)…
Myelodysplastic Syndromes
Primary: Overall Response Rate (ORR) — 12; 0; 0; 0 participants
Myelodysplastic Syndromes
Primary: Participants Who Achieved Red Blood Cell (RBC) -Transfusion Independence — 59 participants
Leukemia · Myelodysplastic Syndromes · Myelodysplastic/Myeloproliferative Neoplasms
Primary: Complete Response Rate — 35.3 percentage of participants